MedTrace Logo

Effect of Brimonidine on Corneal Thickness

NCT01250236 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2010-12-03

No results posted yet for this study

Summary

Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

Conditions

  • Impact of Brimonidine on the Cornea

Interventions

DRUG

brimonidine 0.1%

brimonidine 0.1% eye drops twice daily

DRUG

placebo

sodium hyaluronate 1.8mg/ml eye drops twice daily

Sponsors & Collaborators

  • Augenarztpraxis Breisach

    lead OTHER

Principal Investigators

  • Matthias Grueb, Priv. Doz. Dr. · Augenarztpraxis Breisach

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250236 on ClinicalTrials.gov